Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

<p>Management of Treatment-Resistant Depression: Challenges and Strategies</p>
Daphne Voineskos, Zafiris J. Daskalakis, Daniel M. Blumberger
Neuropsychiatric Disease and Treatment (2020) Vol. Volume 16, pp. 221-234
Open Access | Times Cited: 313

Showing 1-25 of 313 citing articles:

Depression
Robert M. McCarron, Bryan B. Shapiro, Jody Rawles, et al.
Annals of Internal Medicine (2021)
Closed Access | Times Cited: 317
Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review
Kwonmok Ko, Gemma Knight, James Rucker, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 168
Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life
Guy M. Goodwin, Scott T. Aaronson, Oscar Alvarez, et al.
Journal of Affective Disorders (2023) Vol. 327, pp. 120-127
Open Access | Times Cited: 103
Mobile cognition: imaging the human brain in the ‘real world’
Matthias Stangl, Sabrina L. Maoz, Nanthia Suthana
Nature reviews. Neuroscience (2023) Vol. 24, Iss. 6, pp. 347-362
Open Access | Times Cited: 100
Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis
Kwonmok Ko, Emma I Kopra, Anthony J. Cleare, et al.
Journal of Affective Disorders (2022) Vol. 322, pp. 194-204
Closed Access | Times Cited: 90
Anti-Inflammatory, Antioxidant, and Neuroprotective Effects of Polyphenols—Polyphenols as an Element of Diet Therapy in Depressive Disorders
Anna Winiarska‐Mieczan, Małgorzata Kwiecień, Karolina Jachimowicz-Rogowska, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2258-2258
Open Access | Times Cited: 54
BDNF Unveiled: Exploring Its Role in Major Depression Disorder Serotonergic Imbalance and Associated Stress Conditions
Ana Salomé Correia, Armando Cardoso, Nuno Vale
Pharmaceutics (2023) Vol. 15, Iss. 8, pp. 2081-2081
Open Access | Times Cited: 51
Are “mystical experiences” essential for antidepressant actions of ketamine and the classic psychedelics?
Kenji Hashimoto
European Archives of Psychiatry and Clinical Neuroscience (2024)
Open Access | Times Cited: 29
Treatment-Resistant Depression in Older Adults
David C. Steffens
New England Journal of Medicine (2024) Vol. 390, Iss. 7, pp. 630-639
Open Access | Times Cited: 23
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Konstantinos Ν. Fountoulakis, Athanasios Saitis, Alan F. Schatzberg
American Journal of Psychiatry (2025)
Closed Access | Times Cited: 11
Novel drug developmental strategies for treatment‐resistant depression
Éva Borbély, Mária Simon, Eberhard Fuchs, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 6, pp. 1146-1186
Open Access | Times Cited: 71
What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications
Adele Framer
Therapeutic Advances in Psychopharmacology (2021) Vol. 11
Open Access | Times Cited: 57
Non-invasive transcranial brain modulation for neurological disorders treatment: A narrative review
Ethar Ahmed Mosilhy, Eman E. Alshial, Mennatullah Mohamed Eltaras, et al.
Life Sciences (2022) Vol. 307, pp. 120869-120869
Closed Access | Times Cited: 56
Neutrophil/lymphocyte, platelet/lymphocyte and monocyte/lymphocyte ratios in patients with affective disorders
YanYan Wei, Junhui Feng, Jinbao Ma, et al.
Journal of Affective Disorders (2022) Vol. 309, pp. 221-228
Closed Access | Times Cited: 40
Biological Role of Nutrients, Food and Dietary Patterns in the Prevention and Clinical Management of Major Depressive Disorder
Miguel Á. Ortega, Oscar Fraile‐Martínez, Cielo García‐Montero, et al.
Nutrients (2022) Vol. 14, Iss. 15, pp. 3099-3099
Open Access | Times Cited: 40
Discovering the Potential Mechanisms of Medicinal Mushrooms Antidepressant Activity: A Review
Jan Lazur, Kamil Hnatyk, Katarzyna Kała, et al.
Antioxidants (2023) Vol. 12, Iss. 3, pp. 623-623
Open Access | Times Cited: 35
Dissecting the Relationship Between Neuropsychiatric and Neurodegenerative Disorders
Rohan Gupta, Dia Advani, Divya Yadav, et al.
Molecular Neurobiology (2023) Vol. 60, Iss. 11, pp. 6476-6529
Closed Access | Times Cited: 23
New and emerging treatments for major depressive disorder
Cecilia Njenga, Parashar Pravin Ramanuj, Frederico Jose Coelho de Magalhães, et al.
BMJ (2024), pp. e073823-e073823
Closed Access | Times Cited: 13
Treatment-Resistant Depression
Marcus Hughes, Steven R. Levine
Elsevier eBooks (2024)
Closed Access | Times Cited: 10
Omics approaches open new horizons in major depressive disorder: from biomarkers to precision medicine
Fabiola Stolfi, Hugo Abreu, Riccardo Sinella, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 9
Vagus nerve stimulation (VNS): recent advances and future directions
Christopher W. Austelle, Stewart S. Cox, Kristin E Wills, et al.
Clinical Autonomic Research (2024)
Open Access | Times Cited: 9
Is there a risk of esketamine misuse in clinical practice?
Carlos Roncero, M. Merizalde Torres, Néstor Szerman, et al.
Therapeutic Advances in Drug Safety (2025) Vol. 16
Open Access | Times Cited: 1
Comparison of effectiveness and side effects of selegiline transdermal system versus oral monoamine oxidase inhibitors and tricyclic antidepressants for treatment-resistant depression
Thomas T. Kim, Colin Xu, Jay D. Amsterdam
Journal of Affective Disorders (2025) Vol. 376, pp. 47-51
Closed Access | Times Cited: 1
Real-world evidence from a European cohort study of patients with treatment resistant depression: Treatment patterns and clinical outcomes
K. Heerlein, Giulio Perugi, Christian Otte, et al.
Journal of Affective Disorders (2021) Vol. 290, pp. 334-344
Open Access | Times Cited: 52
No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial
Bernhard T. Baune, Emma Sampson, Jennie Louise, et al.
European Neuropsychopharmacology (2021) Vol. 53, pp. 34-46
Closed Access | Times Cited: 44
Page 1 - Next Page

Scroll to top